In deal with Taiho and Astex, Merck gains another K-Ras program

Merck gains another avenue to a target of growing importance via a deal with two Otsuka subsidiaries

A deal giving Merck rights to an oncology program targeting K-Ras could help the pharma further extend its dominance in lung cancer beyond market-leading PD-1 inhibitor Keytruda -- a therapy that has already shown effects on K-Ras mutant disease.

Merck & Co. Inc.

Read the full 422 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE